Stocks · Healthcare · Biotechnology
Acadia Pharmaceuticals Inc. ACAD
$19.95 +0.30% Close, Oct 2, 2026 · NASDAQ · Market cap $3.42B
Inexpensive vs sectorLow risk
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to 7.6% from 23.2% a year earlier.
- Diluted EPS over the last four quarters was $2.22, up 66.9% year over year.
- At 9.0× trailing earnings, the shares trade at the lowest P/E of the company's past five years.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 44%
- EPS growth (TTM, YoY)Top 21%
- FCF growth (TTM, YoY)Bottom 35%
- Revenue growth, 3-year CAGRTop 24%
- Revenue growth accelerationTop 30%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 22%
- Gross marginTop 18%
- Operating marginTop 31%
- Cash conversion (OCF / net income)Bottom 12%
- Accruals (lower is better)Bottom 7%
- Net debt / EBITDA (lower is better)Top 11%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 2%
- Free-cash-flow yieldTop 18%
- EBITDA / enterprise valueTop 28%
- Sales / enterprise valueTop 35%
- P/E vs own 5-year history (lower is better)Top 6%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 41%
- 6-month returnBottom 32%
- 1-year return vs S&P 500Bottom 39%
- Distance from 52-week highBottom 46%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyBottom 39%
- Upside to consensus price targetTop 49%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 31%
- Maximum drawdown, 3 yearsTop 29%
- Beta vs S&P 500 (lower is better)Bottom 47%
- Net debt / EBITDA (lower is better)Top 11%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 9.9% | 11.8% | ↑ |
| EPS growth (YoY) | 60.6% | 66.9% | ↑ |
| Gross margin | 92.0% | 91.1% | ↓ |
| Operating margin | 23.2% | 7.6% | ↓ |
| FCF margin | 18.4% | 15.3% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 11.8% | 9.9% | ↑ | Top 44% |
| EPS growth (TTM, YoY) | 66.9% | 60.6% | ↑ | Top 21% |
| Gross margin | 91.1% | 92.0% | ↓ | Top 18% |
| Operating margin | 7.6% | 23.2% | ↓ | Top 31% |
| Net margin | 33.4% | 21.8% | ↑ | — |
| Free-cash-flow margin | 15.3% | 18.4% | ↓ | — |
| Return on invested capital | 6.2% | — | Top 22% | |
| Revenue growth, 3-year CAGR | 27.5% | — | Top 24% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 0.51×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 10.7%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 5.2%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +27.2 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -2.68×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -1.49%
- Shareholder yield
- -1.49%
- Share count change, 1 year
- +2.5%
- Share count change, 3-year CAGR
- +1.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- +1.7%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $32.32
- Target vs current price
- +62.0%
- Analysts with a rating
- 37
- Share rating Buy or Strong Buy
- 70%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 4, 2026 | +164.1% | +6.0% | +14.8% | +12.9% | — |
| May 6, 2026 | -50.0% | -3.9% | -2.8% | -4.1% | +15.7% |
| Feb 25, 2026 | +1067.9% | +1.5% | -8.5% | -14.8% | -14.8% |
| Nov 5, 2025 | +200.0% | +2.2% | +8.6% | +18.4% | +19.6% |
| Aug 6, 2025 | +14.3% | +0.7% | +7.7% | +8.8% | -4.7% |
| May 7, 2025 | +10.0% | +1.9% | +18.3% | +49.7% | +61.8% |
| Feb 26, 2025 | +352.6% | -0.1% | -3.9% | -10.0% | +14.9% |
| Nov 6, 2024 | +42.9% | +5.3% | +19.5% | +14.5% | +24.9% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | $0.18 | $0.07 | +164.1% | $308.0M |
| May 6, 2026 | $0.02 | $0.04 | -50.0% | $268.1M |
| Feb 25, 2026 | $1.60 | $0.14 | +1067.9% | $284.0M |
| Nov 5, 2025 | $0.42 | $0.14 | +200.0% | $278.6M |
| Aug 6, 2025 | $0.16 | $0.14 | +14.3% | $264.6M |
| May 7, 2025 | $0.11 | $0.10 | +10.0% | $244.3M |
| Feb 26, 2025 | $0.86 | $0.19 | +352.6% | $259.6M |
| Nov 6, 2024 | $0.20 | $0.14 | +42.9% | $250.4M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 9.0× | 14.0× | 0th | Top 2% |
| P/E (forward) | 32.4× | — | — | — |
| EV / EBITDA | 26.7× | — | — | Top 28% |
| EV / Sales | 2.73× | — | — | Top 35% |
| Free-cash-flow yield | 5.10% | — | — | Top 18% |
| Earnings yield | 11.13% | — | — | Top 2% |
P/E over the past five years
Range 10.3× – 84.3× since Jun 30, 2024. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- -6.1%
- Earnings per share growth (TTM)
- +66.9%
- Change in P/E multiple
- -29.3%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -0.9%
- 200-day average slope (20 days)
- -0.2%
- Distance from 50-day average
- -26.0%
- Distance from 200-day average
- -18.2%
- RSI (14)
- 16.3
- Relative volume
- 1.13×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 45.7%
- Volatility vs own 5-year history
- 44th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.17
- Correlation with S&P 500
- 0.37
- Current drawdown from 1-year high
- -34.7%
- Maximum drawdown, 3 years
- -55.6%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 1, 2020 | Jun 21, 2022 | -77.1% | 390 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $3.42B
- P/E (TTM)
- 9.0
- EPS, diluted (TTM)
- $2.22
- Revenue (TTM)
- $1.14B
- 52-week range
- $19.59 – $30.96
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $484.1M | $517.2M | $726.4M | $957.8M | $1.07B |
| Gross profit | $465.0M | $507.1M | $680.7M | $876.0M | $982.5M |
| Operating income | -$170.4M | -$223.6M | -$73.4M | $230.8M | $104.8M |
| Net income | -$167.9M | -$216.0M | -$61.3M | $226.5M | $391.0M |
| EPS (diluted) | -$1.05 | -$1.34 | -$0.37 | $1.36 | $2.29 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $250.4M | $259.6M | $244.3M | $264.6M | $278.6M | $284.0M | $268.1M | $308.0M |
| Net income | $32.8M | $143.7M | $19.0M | $26.7M | $71.8M | $273.6M | $3.6M | $31.5M |
| EPS (diluted) | $0.20 | $0.86 | $0.11 | $0.16 | $0.42 | $1.60 | $0.02 | $0.18 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$125.7M | -$114.0M | $16.7M | $157.7M | $109.8M |
| Capital expenditure | -$1.1M | $0 | -$40.0M | -$523,000 | -$4.7M |
| Free cash flow | -$126.8M | -$114.0M | -$23.3M | $157.2M | $105.1M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $18.2M | $8.2M | $25.1M | $6.8M | $49.9M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $956.5M
- Total assets
- $1.74B
- Total liabilities
- $436.3M
- Total debt
- $73.9M
- Net debt
- -$311.1M
- Shareholders’ equity
- $1.31B
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 9,666,972
- Days to cover
- 7.22
- Change vs previous report
- -0.8%
FINRA short interest, settlement date Sep 15, 2026.